ClinicalTrials.gg
CompletedNCT05877235Updated Dec 19, 2025

Serum Concentration of Endogenous Estrogens and Sirtuin-1 After Administration of Atorvastatin and Quercetin:

An interventional study of Quercetin and Placebo in Coronary Artery Disease and Menopause, sponsored by InCor Heart Institute. Completed at 1 site in Brazil. Open to female participants aged 55 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by InCor Heart Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Oct 2021, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
55 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 29 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.

Enrollment
77th of 123
60 · median 100
Started
2021
with 7 others
No phase
67 of 152
14 open now
Registered
130th of 152
by date
Lead sponsor
6 of 152
InCor Heart Institute

Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 77th largest by enrollment of the 123 interventional ones that give a count, is one of 8 that started in 2021, is one of 67 with no phase, and was the 130th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 55 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Coronary Artery Disease with a site in Brazil, or all of them as a file.
02

Study summary

Chronic coronary syndrome (CCS) is the leading cause of death in women in the most developed regions of Brazil. The primary etiopathogenic mechanism is the process of atherosclerosis. A healthy diet rich in fruits and vegetables is associated with a lower incidence of CCS. The higher consumption of these foods promotes greater availability of phenolic compounds, and the higher intake of these compounds is one of the main hypotheses for vascular health. Quercetin, a phenolic compound, is the most abundant natural antioxidant belonging to the group of flavonoids. Quercetin improves lipoprotein metabolism, has an antioxidant capacity, produces vasodilating substances in the vascular endothelium, and reduces platelet aggregability. Likewise, statins are medications known to reduce cardiovascular events in women with CCS by reducing serum LDL-cholesterol levels and, to a lesser extent, by possible pleiotropic effects. In turn, SIRT1 is one of the 7 classes of proteins. It mediates various metabolic pathways in response to nutritional stimuli, particularly for caloric restriction and phenolic compounds, as well as coordinating the production and secretion of important hormones. However, the impact of quercetin supplementation and statin administration on serum endogenous estrogen levels is unknown

Read the detailed description

The main objective of this study is to investigate the influence of atorvastatin and of quercetin in the serum concentrations of estradiol and estrone after the administration of atorvastatin and supplementation with quercetin. This is a randomized, double-blind, placebo-controlled, 60-day study in 60 postmenopausal women with CAD, divided into three groups of 20 women each: Group 1 - quercetin (500 mg/day); Group 2 - atorvastatin (80 mg/day); Group 3 - control (placebo).

03

Conditions studied

  • Coronary Artery Disease
  • Menopause

Keywords

  • Coronary disease
  • Atherosclerosis
  • Estradiol
  • Estrone
  • Sirt1
  • Quercetin
  • Atorvastatin
  • Polyphenols
04

Who can participate

Ages eligible
55 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women;
  • Diagnosed coronary artery disease;
  • Stable coronary disease;

Exclusion criteria

Exclusion Criteria:

  • hypo or hyperthyroidism,
  • rheumatic disease,
  • use of alcohol,
  • hepatic failure,
  • renal failure
  • hormone replacement therapy
  • use of insulin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Quercetin

    Trans-quercetin, 1000 mg daily for 60 days

    Dietary Supplement: Quercetin

  • Experimental
    Atorvastatin

    Atorvastatin, 80mg daily for 60 days.

    Dietary Supplement: Quercetin

  • Placebo comparator
    Control

    Starch, 1000mg daily for 60 days.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementQuercetin

    Trans-quercetin, 1000 mg daily for 60 days

  • Dietary supplementPlacebo

    Starch, 1000 mg daily for 60 days

06

What researchers measure

Primary outcomes

  1. Estradiol

    serum concentrations

    Time frame: 60 days

  2. Estrone

    serum concentrations

    Time frame: 60 days

  3. Sirtuin-1

    Serum concentrations and gene expression

    Time frame: 60 days

Secondary outcomes

  1. Cardiometabolic risk factors

    Lipid and glucometabolic profiles

    Time frame: 60 days

07

Study locations

1 site
  • INCOR- Heart Institute
    São Paulo, São Paulo 05403900, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Dec 2023, 26 months.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 26 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 26, 2023
StartActual
Oct 3, 2021
Primary completionActual
Dec 23, 2023
CompletionActual
Jun 23, 2024
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05877235
Lead sponsor
InCor Heart Institute
Responsible party
ANTONIO DE PADUA MANSUR (Associate Professor, InCor Heart Institute) — Principal investigator
First posted
May 26, 2023
Start date
Oct 3, 2021
Primary completion
Dec 23, 2023
Completion
Jun 23, 2024
Last update
Dec 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quercetin

Start the discussion